Durham startup Tune Therapeutics raises $175 million

Durham biotech startup raises $175 million as it starts novel gene therapy trial
It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.
Durham biotech firm Tune Therapeutics has raised a $175 million funding round
A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its treatment that tunes gene activity within the body. Why it matters: The fundraising round by Tune Therapeutics is one of the largest in the Triangle in recent months and will give the company runway to collect more data on its leading drug,
Durham's Tune Therapeutics raises $175M in venture capital
Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.
Epigenetic biotech raises bumper round to the Tune of $175M to fund entry into clinic
Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic.
Seattle biotech startup Tune Therapeutics lands $175M to support clinical research
Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.
Seattle biotech company raises $100 million
Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to ...
BioPharma Dive3d
Tune raises $175M for hepatitis B medicine, epigenetic research
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...
precisionmedicineonline2d
Tune Therapeutics Raises $175M in Series B Financing to Fund Hepatitis B Epigenetic Silencing Drug
Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.
ncbiotech.org7d
Durham’s Tavros Therapeutics sold to subsidiary of German giant Bayer AG
Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...
Tune Therapeutics Receives Approval to Initiate Clinical Trial in Hong Kong for HepB Epigenetic Silencer
Leading epigenetic therapy company Tune Therapeutics announced today that it will begin a clinical trial in Hong Kong after receiving a Certificate for Clinical Trial from the Hong Kong Department of ...
Durham company secures whopping $175M to develop innovative drugs
A biotechnology company in Durham has closed a $175 million funding round to support its efforts to develop new ways of tackling major diseases.